<DOC>
	<DOCNO>NCT00460811</DOCNO>
	<brief_summary>The purpose study determine safety , efficacy , dose response range oral dos linaclotide administer patient meet criteria IBS-C .</brief_summary>
	<brief_title>Randomized , Double-blind , Dose-range-finding , Phase 2 Study Linaclotide Administered Patients With Irritable Bowel Syndrome With Constipation ( IBS-C )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Must pregnant breastfeeding agree use birth control ; Completion negative colonoscopy per American Gastroenterology Association ( AGA ) criteria clinicallysignificant laboratory physical examination finding ; Meets protocoldefined criterion IBSC , include stool frequency , strain , stool consistency , abdominal pain , abdominal discomfort criterion ; Demonstrates English fluency access touchtone telephone . Recent history mushy watery stool ; Various medical condition , medical history , family medical history would make patient good candidate study ; Clinicallysignificant alarm symptom ; Secondary cause constipation evacuation disorder ; Surgery gastrointestinal tract ; Usage prohibit medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Irritable Bowel Syndrome Constipation</keyword>
	<keyword>IBS</keyword>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>linaclotide acetate</keyword>
	<keyword>linaclotide</keyword>
	<keyword>MD-1100</keyword>
</DOC>